Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Topical macrolide antibiotic (anti-acne)

Erythromycin 2% Topical

Brand names: Stiemycin (2% solution), Zineryt (erythromycin 4% + zinc acetate 1.2%)

Topical erythromycin is a macrolide antibacterial solution or gel applied to the skin for mild-to-moderate inflammatory acne vulgaris.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Applied locally it inhibits bacterial protein synthesis by binding the 50S ribosomal subunit, suppressing Cutibacterium acnes, and also has a local anti-inflammatory effect.

Prescribing in practice

  • To limit bacterial resistance, topical erythromycin should be combined with benzoyl peroxide rather than used as prolonged antibiotic monotherapy, and treatment courses kept time-limited.
  • Avoid concurrent use of other topical or oral antibiotics from a different class to reduce selection of resistant organisms.
  • Apply to the whole affected area rather than spot-treating, and avoid the eyes, mouth and mucous membranes.

Monitoring

No laboratory monitoring is needed; review acne response and local tolerability, and reassess the need to continue to avoid resistance.

Counselling the patient

  • Apply a thin layer to the entire affected area of clean, dry skin, not just to individual spots.
  • Use any benzoyl peroxide product as advised to keep the treatment working and reduce resistance.
  • Improvement may take several weeks; mild dryness or stinging can occur.

Evidence & guidelines

Topical antibiotics combined with benzoyl peroxide are recommended for acne in NICE guidance, which advises against antibiotic monotherapy to limit resistance.

Reference: BAD Acne Guidelines 2021; NICE CG184; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways